(Q53336336)

13 May 2018

title

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. (English)

1 reference

13 May 2018

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

1 reference

2

Hagop Kantarjian

1 reference

13 May 2018

5

Stefan Faderl

1 reference

13 May 2018

9

William Wierda

1 reference

13 May 2018

4

Susan O'Brien

1 reference

13 May 2018

6

Farhad Ravandi

1 reference

13 May 2018

7

Francis Giles

1 reference

13 May 2018

Guillermo Garcia-Manero

series ordinal

3

object named as

Guillermo Garcia-Manero

1 reference

13 May 2018

10

Jorge Cortes

1 reference

13 May 2018

author name string

Alfonso Quintás-Cardama

series ordinal

1

1 reference

13 May 2018

Deborah Thomas

series ordinal

8

1 reference

13 May 2018

publication date

1 February 2007

1 reference

13 May 2018

published in

Leukemia & Lymphoma

1 reference

13 May 2018

volume

48

1 reference

13 May 2018

issue

2

1 reference

13 May 2018

page(s)

283-289

1 reference

13 May 2018

The biology of chronic myeloid leukemia

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601075973

10.1080/10428190601075973

21 January 2018

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018